ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2020
Mucosal Vaccination for Influenza Protection Enhanced by Catalytic Immune-Adjuvant.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Mucosal immune response in biology, disease prevention and treatment.Signal transduction and targeted therapy · 2025Pooled it
- Emerged N193S mutation of PA-X protein disabled the immunity of mucosal dendritic cells for regulating virulence of clade 2.3.4.4b H5 subtype virus.Emerging microbes & infections · 2026Article
- Combating respiratory diseases with mucosal vaccines.Journal of virology · 2026Review
- Intranasal Vaccine Adjuvants and Delivery Platforms: From Barrier Mechanisms to Clinical Translation.Vaccines · 2026Review
- Liposomal simvastatin potentiates intranasal H1N1 influenza subunit vaccineActa pharmaceutica Sinica. B · 2026Article
- A Prussian Blue Nanozyme-Adjuvanted Vaccine Presenting Phosphocholine Antigens for Induction of Immunotolerance in Inflammatory Bowel Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- SMart Nanoparticle-Hydrogel Hybrid System for Synergistic Eradication of Infection and Promotion of Wound Healing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Antimicrobial Nanozymes: Structure-Activity-Guided Design, Synergy, and Applications.Research (Washington, D.C.) · 2026Review
- A dual-enzyme-like nanozyme adjuvant alleviates tumor hypoxia to enhance photothermally ferroptosis-immune synergistic tumor therapy.Materials today. Bio · 2025Article
- Polyethyleneimine-modifiedMaterials today. Bio · 2025Article
- Detection of Antibodies Specific to H5 Avian Influenza Virus in a Sheep in Norway, June 2024, 11 Months After an Outbreak of Highly Pathogenic Avian Influenza in a Nearby Seabird Colony.Influenza and other respiratory viruses · 2025Article
- Immune Responses of Dendritic Cells to Zoonotic DNA and RNA Viruses.Veterinary sciences · 2025Review
- Mucosal immunotherapy targeting APC in lung disease.Journal of inflammation (London, England) · 2025Review
- Nano-Emulsion Incorporating Squalene and MnInternational journal of nanomedicine · 2025Article
- Mucosal immunization with the lung Lactobacillus-derived amphiphilic exopolysaccharide adjuvanted recombinant vaccine improved protection against P. aeruginosa infection.PLoS pathogens · 2024Article
- Immunostimulatory effects of Toll-like receptor ligands as adjuvants in establishing a novel mouse model for pemphigus vulgaris.Clinical and translational medicine · 2024Article
- Utilizing nanozymes for combating COVID-19: advancements in diagnostics, treatments, and preventative measures.Journal of nanobiotechnology · 2023Review
- Progress of polymer-based strategies in fungal disease management: Designed for different roles.Frontiers in cellular and infection microbiology · 2023Review
- PA-X protein of H1N1 subtype influenza virus disables the nasal mucosal dendritic cells for strengthening virulence.Virulence · 2022Article
- The influenza virus PB2 protein evades antiviral innate immunity by inhibiting JAK1/STAT signalling.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza poses a severe threat to global health. Despite the whole inactivated virus (WIV)-based nasal vaccine being a promising strategy for influenza protection, the mucosal barrier is still a bottleneck of the nasal vaccine. Here, a catalytic mucosal adjuvant strategy for an influenza WIV nasal vaccine based on chitosan (CS) functionalized iron oxide nanozyme (IONzyme) is developed. The results reveal that CS-IONzyme increases antigen adhesion to nasal mucosa by 30-fold compared to H1N1 WIV alone. Next, CS-IONzyme facilitates H1N1 WIV to enhance CCL20-driven submucosal dendritic cell (DC) recruitment and transepithelial dendrite(TED) formation for viral uptake via the toll-like receptor(TLR) 2/4-dependent pathway. Moreover, IONzyme with enhanced peroxidase (POD)-like activity by CS modification catalyzes a reactive oxygen species (ROS)-dependent DC maturation, which further enhances the migration of H1N1 WIV-loaded DCs into the draining lymph nodes for antigen presentation. Finally, CS-IONzyme-based nasal vaccine triggers an 8.9-fold increase of IgA-mucosal adaptive immunity in mice, which provides a 100% protection against influenza, while only a 30% protection by H1N1 WIV alone. This work provides an antiviral alternative for designing nasal vaccines based on IONzyme to combat influenza infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.